Paper36650528
An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells.
Yoshida M and 5 others. Cancer Cell Int, 2023. Cited by 13 papers, by iCite.
Cite this record
ConductScience Library. An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells. Papers, record 36650528. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36650528
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| JP22am0401003 | Japan Agency for Medical Research and Development | PubMed | ||
| 22K07230 | Japan Society for the Promotion of Science | PubMed |
Source PubMed
References46
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33621242 | Silencing of SRRM4 suppresses microexon inclusion and promotes tumor growth across cancers. | PLoS Biol | 2021 | https://conductscience.org/library/papers/33621242 | PubMed |
| 2 | 33482121 | Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. | Cancer Cell | 2021 | https://conductscience.org/library/papers/33482121 | PubMed |
| 3 | 31912902 | Cancer statistics, 2020. | CA Cancer J Clin | 2020 | https://conductscience.org/library/papers/31912902 | PubMed |
| 4 | 2985258 | Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. | Cancer Res | 1985 | https://conductscience.org/library/papers/2985258 | PubMed |
| 5 | 30926931 | Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. | Nat Rev Cancer | 2019 | https://conductscience.org/library/papers/30926931 | PubMed |
| 6 | 29240946 | Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. | Nucleic Acids Res | 2018 | https://conductscience.org/library/papers/29240946 | PubMed |
| 7 | 29077690 | Small-cell lung cancer: what we know, what we need to know and the path forward. | Nat Rev Cancer | 2017 | https://conductscience.org/library/papers/29077690 | PubMed |
| 8 | 16265346 | Neuronal characteristics of small-cell lung cancer. | Br J Cancer | 2005 | https://conductscience.org/library/papers/16265346 | PubMed |
| 9 | 31110284 | A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer. | Sci Rep | 2019 | https://conductscience.org/library/papers/31110284 | PubMed |
| 10 | 30987806 | Intratumoral Heterogeneity: More Than Just Mutations. | Trends Cell Biol | 2019 | https://conductscience.org/library/papers/30987806 | PubMed |
| 11 | 20548947 | The transcription factor REST is lost in aggressive breast cancer. | PLoS Genet | 2010 | https://conductscience.org/library/papers/20548947 | PubMed |
| 12 | 33574607 | Intratumoral heterogeneity in cancer progression and response to immunotherapy. | Nat Med | 2021 | https://conductscience.org/library/papers/33574607 | PubMed |
| 13 | 20011975 | Genome-wide identification of target genes repressed by the zinc finger transcription factor REST/NRSF in the HEK 293 cell line. | Acta Biochim Biophys Sin (Shanghai) | 2009 | https://conductscience.org/library/papers/20011975 | PubMed |
| 14 | 31036929 | Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. | Nat Biotechnol | 2019 | https://conductscience.org/library/papers/31036929 | PubMed |
| 15 | 16139198 | Transcriptional regulation: cancer, neurons and the REST. | Curr Biol | 2005 | https://conductscience.org/library/papers/16139198 | PubMed |
| 16 | 27452466 | ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. | Cell Rep | 2016 | https://conductscience.org/library/papers/27452466 | PubMed |
| 17 | 28089889 | MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. | Cancer Cell | 2017 | https://conductscience.org/library/papers/28089889 | PubMed |
| 18 | 32403054 | Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4. | Neoplasia | 2020 | https://conductscience.org/library/papers/32403054 | PubMed |
| 19 | 27180064 | SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. | Eur Urol | 2017 | https://conductscience.org/library/papers/27180064 | PubMed |
| 20 | 31525487 | Clinical features of neuroendocrine prostate cancer. | Eur J Cancer | 2019 | https://conductscience.org/library/papers/31525487 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40746825 | New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic. | Research (Wash D C) | 2025 | https://conductscience.org/library/papers/40746825 | PubMed |
| 40133523 | Multi-center study: ultrasound-based deep learning features for predicting Ki-67 expression in breast cancer. | Sci Rep | 2025 | https://conductscience.org/library/papers/40133523 | PubMed |
| 39377066 | Splice-switching antisense oligonucleotide controlling tumor suppressor REST is a novel therapeutic medicine for neuroendocrine cancer. | Mol Ther Nucleic Acids | 2024 | https://conductscience.org/library/papers/39377066 | PubMed |
| 39304746 | Dual-modified antisense oligonucleotides targeting oncogenic protocadherin to treat gastric cancer. | Br J Cancer | 2024 | https://conductscience.org/library/papers/39304746 | PubMed |
| 38658776 | Alternative splicing in prostate cancer progression and therapeutic resistance. | Oncogene | 2024 | https://conductscience.org/library/papers/38658776 | PubMed |
| 38621757 | A novel transient receptor potential C3/C6 selective activator induces the cellular uptake of antisense oligonucleotides. | Nucleic Acids Res | 2024 | https://conductscience.org/library/papers/38621757 | PubMed |
| 37892159 | REST Is Not Resting: REST/NRSF in Health and Disease. | Biomolecules | 2023 | https://conductscience.org/library/papers/37892159 | PubMed |
| 37761978 | Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37761978 | PubMed |
| 37736898 | Non-Coding RNAs: Foes or Friends for Targeting Tumor Microenvironment. | Noncoding RNA | 2023 | https://conductscience.org/library/papers/37736898 | PubMed |
| 37662844 | Nucleic acid-based therapeutics for the treatment of central nervous system disorders. | Front Genet | 2023 | https://conductscience.org/library/papers/37662844 | PubMed |
| 37514088 | Recent Progress in Extracellular Vesicle-Based Carriers for Targeted Drug Delivery in Cancer Therapy. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37514088 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CASP3 | 836 | PubTator's text mining | https://conductscience.org/library/genes/836 | NCBI Gene |
| CASP7 | 840 | PubTator's text mining | https://conductscience.org/library/genes/840 | NCBI Gene |
| MBL3P | 50639 | PubTator's text mining | https://conductscience.org/library/genes/50639 | NCBI Gene |
| POTEF | 728378 | PubTator's text mining | https://conductscience.org/library/genes/728378 | NCBI Gene |
| REST | 5978 | PubTator's text mining | https://conductscience.org/library/genes/5978 | NCBI Gene |
| SRRM4 | 84530 | PubTator's text mining | https://conductscience.org/library/genes/84530 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36650528
GET https://conductscience.org/api/papers/v1/36650528/references?page=2